Press Releases

Featured Press Releases

BIO Statement Regarding Nomination of Robert F…

BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…

Learn more

BIO Released the Following Statement After…

“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…

Learn more

BIO Statement on Lawsuit Over 340B Rebates

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…

Learn more

BIO CEO & Investor Conference Programming Announced

December 15, 2016

BIO announced programming for the 19th annual BIO CEO & Investor Conference. Held February 13-14 at the Waldorf Astoria in New York, the annual conference provides an environment for investors, analysts, industry executives and others to…

BIO Applauds Senate Passage of the 21st Century Cures Act

December 7, 2016

Washington, DC (December 7, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. Senate:

BIO Applauds House Passage of the 21st Century Cures Act

November 30, 2016

Washington, DC (November 30, 2016) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the 21st Century Cures Act by the U.S. House of Representatives:

BIO Responds to GAO Report Declaring RFS Will Not Meet Goals

November 29, 2016

BIO responds to GAO's latest report on the Renewable Fuel Standard (RFS), “Renewable Fuel Standard, Program Unlikely to Meet its Targets for Reducing Greenhouse Gas Emissions.” GAO correctly concludes the technology is available for advance biofuels…

BIO Welcomes EPA’s Final 2017 Renewable Fuel Standards

November 23, 2016

The Environmental Protection Agency’s final Renewable Fuel Standards for 2017 and biomass-based diesel volume for 2018 appear to put the program back on track and will provide considerable additional certainty for investors in advanced and…

BIO Statement on FDA Product Communications Hearing

November 9, 2016

BIO President and CEO Jim Greenwood released the following statement today regarding the FDA’s hearing on product communications:“In the era of data-driven medicine, where all parties seek more, not less, information about the safety,…

BIO Patient and Health Advocacy Summit Hosts Over 300 Attendees from Wide Range of Health Care Organizations

November 4, 2016

Over 200 diverse groups were represented at the November 3-4 meeting in Washington, D.C.

BIO Issues Call for Papers for 2017 World Congress on Industrial Biotechnology in Montréal

November 1, 2016

BIO has officially issued a call to leaders from the biotechnology, bioenergy, chemical, consumer products manufacturing, and agricultural industries as well as academia and financial sectors industries to submit panel session proposals for the…

BIO Asks Congress to Extend Critical Bioenergy Tax Credits During Lame-Duck

October 18, 2016

BIO today sent a letter to Congressional Leadership, the Senate Finance Committee Chairs, and the House Ways and Means Committee Chairs calling for the extension of renewable energy tax credits slated to expire at the end of 2016. In its letter…

BIO Names Dana O’Brien Executive Vice President for Food & Agriculture Section

October 13, 2016

BIO announced today that Dana O’Brien has been named BIO’s Executive Vice President for its Food & Agriculture Section.

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.